<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="sciences : Microbiology : Medical microbiology : Microbial pathogens :" exact="Viral" post="pathogens : Hepatitis viruses: Hepatitis B virus : Medicine"/>
 <result pre=": Medical microbiology : Microbial pathogens : Viral pathogens :" exact="Hepatitis" post="viruses: Hepatitis B virus : Medicine and health sciences"/>
 <result pre="microbiology : Microbial pathogens : Viral pathogens : Hepatitis viruses:" exact="Hepatitis" post="B virus : Medicine and health sciences : Pathology"/>
 <result pre="Pathology and laboratory medicine : Pathogens : Microbial pathogens :" exact="Viral" post="pathogens : Hepatitis viruses: Hepatitis B virus : Biology"/>
 <result pre="medicine : Pathogens : Microbial pathogens : Viral pathogens :" exact="Hepatitis" post="viruses: Hepatitis B virus : Biology and life sciences"/>
 <result pre="Pathogens : Microbial pathogens : Viral pathogens : Hepatitis viruses:" exact="Hepatitis" post="B virus : Biology and life sciences : Organisms"/>
 <result pre=": Biology and life sciences : Organisms : Viruses :" exact="Viral" post="pathogens : Hepatitis viruses: Hepatitis B virus : Medicine"/>
 <result pre="life sciences : Organisms : Viruses : Viral pathogens :" exact="Hepatitis" post="viruses: Hepatitis B virus : Medicine and Health Sciences"/>
 <result pre=": Organisms : Viruses : Viral pathogens : Hepatitis viruses:" exact="Hepatitis" post="B virus : Medicine and Health Sciences : Clinical"/>
 <result pre="Randomized Controlled Trials : Medicine and Health Sciences : Nephrology:" exact="Glomerulonephritis" post=": Medicine and Health Sciences : Pharmacology : Drugs"/>
 <result pre="Pharmacology: Adverse Reactions Efficacy and safety of anti-viral therapy for" exact="Hepatitis" post="B virus-associated glomerulonephritis: A meta-analysis Efficacy and safety of"/>
 <result pre="glomerulonephritis: A meta-analysis Efficacy and safety of anti-viral therapy for" exact="Hepatitis" post="B virus-associated glomerulonephritis FuBaohuiVisualizationWriting – original draftWriting – review"/>
 <result pre="Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated" exact="glomerulonephritis" post="FuBaohuiVisualizationWriting – original draftWriting – review &amp;amp; editing1JiYueVisualizationWriting –"/>
 <result pre="China[3], International Department, Tongji University School of Medicine Affiliated Shanghai" exact="Pulmonary" post="Hospital, Shanghai, China[4], Public Health Science and Engineering College,"/>
 <result pre="Tianjin University of Traditional Chinese Medicine, Tianjin, ChinaSharafiHeidarEditor[], Middle East" exact="Liver Diseases" post="(MELD) Center, ISLAMIC REPUBLIC OF IRAN Competing Interests: The"/>
 <result pre="University of Traditional Chinese Medicine, Tianjin, ChinaSharafiHeidarEditor[], Middle East Liver" exact="Diseases" post="(MELD) Center, ISLAMIC REPUBLIC OF IRAN Competing Interests: The"/>
 <result pre="Abstract Objectives To assess the potency of anti-viral treatment for" exact="hepatitis" post="B virus-associated glomerulonephritis (HBV-GN). Method: We searched for controlled"/>
 <result pre="assess the potency of anti-viral treatment for hepatitis B virus-associated" exact="glomerulonephritis" post="(HBV-GN). Method: We searched for controlled clinical trials on"/>
 <result pre="trials, including 182 patients met the criteria for evaluating. The" exact="primary" post="outcome measures were proteinuria and changes in the estimated"/>
 <result pre="and changes in the estimated glomerular filtration rate, and the" exact="secondary" post="outcome measure was hepatitis B e-antigen clearance. A fixed"/>
 <result pre="estimated glomerular filtration rate, and the secondary outcome measure was" exact="hepatitis" post="B e-antigen clearance. A fixed or random effect model"/>
 <result pre="type, anti-viral drug type, age, and follow-up duration. Results The" exact="total" post="remission rate of proteinuria (OR = 10.48, 95% CI:"/>
 <result pre="proteinuria (OR = 10.48, 95% CI: 4.60−23.89, I2 = 0%)," exact="complete" post="remission rate of proteinuria (OR = 11.64, 95% CI:"/>
 <result pre="95% CI: 5.17−26.21, I2 = 23%) and clearance rate of" exact="Hepatitis" post="Be Antigen (HBeAg) were significantly higher in the anti-viral"/>
 <result pre="and increased HBeAg clearance but failed to improve the eGFR." exact="Pediatric" post="patients were more sensitive to antiviral therapy than adults."/>
 <result pre="Despite the availability of potent antivirals and vaccination against the" exact="hepatitis" post="B virus (HBV), chronic HBV infection remains a significant"/>
 <result pre="potent antivirals and vaccination against the hepatitis B virus (HBV)," exact="chronic" post="HBV infection remains a significant socioeconomic burden. The global"/>
 <result pre="and vaccination against the hepatitis B virus (HBV), chronic HBV" exact="infection" post="remains a significant socioeconomic burden. The global prevalence of"/>
 <result pre="infection remains a significant socioeconomic burden. The global prevalence of" exact="chronic" post="HBV in 2016 was close to 3.9%, which equates"/>
 <result pre="on the liver, patients with HBV have extrahepatic manifestations of" exact="renal disease." post="In a single-center retrospective trial, Zhang et al[2] reported"/>
 <result pre="et al[2] reported that 3% (n = 352) of a" exact="total" post="of 11,618 kidney biopsies performed from 1987 to 2012"/>
 <result pre="inhibitors is still controversial because of the risk of activating" exact="viral" post="infections, so the mainstay of treatment continues to be"/>
 <result pre="therapy. Several drugs are now available for the treatment of" exact="chronic" post="HBV infection and are mainly one of two types:"/>
 <result pre="drugs are now available for the treatment of chronic HBV" exact="infection" post="and are mainly one of two types: nucleos (t)"/>
 <result pre="with HBV surface antigen (HBsAg)-positive serum and were free from" exact="lupus" post="nephritis and other secondary glomerular diseases[13]. Clinical trials meeting"/>
 <result pre="HBV surface antigen (HBsAg)-positive serum and were free from lupus" exact="nephritis" post="and other secondary glomerular diseases[13]. Clinical trials meeting the"/>
 <result pre="(HBsAg)-positive serum and were free from lupus nephritis and other" exact="secondary" post="glomerular diseases[13]. Clinical trials meeting the following criteria were"/>
 <result pre="Self-control studies or case reports. Patients who were diagnosed with" exact="glomerulonephritis" post="but not secondary nephritis caused by the hepatitis B"/>
 <result pre="case reports. Patients who were diagnosed with glomerulonephritis but not" exact="secondary" post="nephritis caused by the hepatitis B virus. 3. Selection"/>
 <result pre="reports. Patients who were diagnosed with glomerulonephritis but not secondary" exact="nephritis" post="caused by the hepatitis B virus. 3. Selection of"/>
 <result pre="diagnosed with glomerulonephritis but not secondary nephritis caused by the" exact="hepatitis" post="B virus. 3. Selection of studies and data extraction"/>
 <result pre="follow-up interval and follow-up duration), and outcomes (including laboratory reports:" exact="complete" post="remission (CR) and partial remission (PR) of proteinuria; estimated"/>
 <result pre="duration), and outcomes (including laboratory reports: complete remission (CR) and" exact="partial" post="remission (PR) of proteinuria; estimated glomerular filtration rate (eGFR);"/>
 <result pre="types, age and follow-up duration. 6. Study outcome measures The" exact="primary" post="outcomes that this systematic review focused on were renal"/>
 <result pre="remission rate and estimated glomerular filtration rate (eGFR), and the" exact="secondary" post="outcome measure was HBeAg clearance. Complete remission (CR) of"/>
 <result pre="rate (eGFR), and the secondary outcome measure was HBeAg clearance." exact="Complete" post="remission (CR) of proteinuria was defined as urinary protein"/>
 <result pre="as urinary protein excretion less 0.3 g in 24 hours." exact="Partial" post="remission (PR) represented a decline in urinary protein excretion"/>
 <result pre="males. In addition, all the HBV-GN patients had kidney biopsies;" exact="membranous nephropathy" post="(MN) was found in 134 patients (73.6%), followed by"/>
 <result pre="In addition, all the HBV-GN patients had kidney biopsies; membranous" exact="nephropathy" post="(MN) was found in 134 patients (73.6%), followed by"/>
 <result pre="nephropathy (MN) was found in 134 patients (73.6%), followed by" exact="IgA nephropathy" post="in 24 (13.2%), membranoproliferative glomerulonephritis (MPGN) in 12 (6.6%),"/>
 <result pre="(MN) was found in 134 patients (73.6%), followed by IgA" exact="nephropathy" post="in 24 (13.2%), membranoproliferative glomerulonephritis (MPGN) in 12 (6.6%),"/>
 <result pre="134 patients (73.6%), followed by IgA nephropathy in 24 (13.2%)," exact="membranoproliferative glomerulonephritis" post="(MPGN) in 12 (6.6%), focal segmental glomerulosclerosis (FSGS) in"/>
 <result pre="patients (73.6%), followed by IgA nephropathy in 24 (13.2%), membranoproliferative" exact="glomerulonephritis" post="(MPGN) in 12 (6.6%), focal segmental glomerulosclerosis (FSGS) in"/>
 <result pre="nephropathy in 24 (13.2%), membranoproliferative glomerulonephritis (MPGN) in 12 (6.6%)," exact="focal segmental glomerulosclerosis" post="(FSGS) in four, other pathological types, such as mesangial"/>
 <result pre="24 (13.2%), membranoproliferative glomerulonephritis (MPGN) in 12 (6.6%), focal segmental" exact="glomerulosclerosis" post="(FSGS) in four, other pathological types, such as mesangial"/>
 <result pre="segmental glomerulosclerosis (FSGS) in four, other pathological types, such as" exact="mesangial proliferative glomerulonephritis" post="(MSPGN) and minimal change nephropathy (MCGP), in two patients"/>
 <result pre="glomerulosclerosis (FSGS) in four, other pathological types, such as mesangial" exact="proliferative glomerulonephritis" post="(MSPGN) and minimal change nephropathy (MCGP), in two patients"/>
 <result pre="(FSGS) in four, other pathological types, such as mesangial proliferative" exact="glomerulonephritis" post="(MSPGN) and minimal change nephropathy (MCGP), in two patients"/>
 <result pre="types, such as mesangial proliferative glomerulonephritis (MSPGN) and minimal change" exact="nephropathy" post="(MCGP), in two patients and IgM nephropathy in one"/>
 <result pre="and minimal change nephropathy (MCGP), in two patients and IgM" exact="nephropathy" post="in one patient. Two patients had combined lesions, with"/>
 <result pre="million units/m2 3 times/week)(n = 19) control of edema and" exact="hypertension" post="(n = 20) 16 weeks 40 weeks 5 ①②③"/>
 <result pre="body weight&amp;gt;20 kg, 3 times/week subcutaneous injection) controlof edema and" exact="hypertension" post="12 mo 24 mo 0 ③ Abbreviations: RCT, randomized"/>
 <result pre="blinding of participants and personnel, blinding of outcome assessment and" exact="incomplete" post="outcome data but had an unclear risk with respect"/>
 <result pre="of antiviral therapy for HBV-GN. We evaluated the CR and" exact="total" post="remission (CR+PR) rates after treatment with a fixed-effect model"/>
 <result pre="(Fig 2). There was no clinical and statistical heterogeneity in" exact="total" post="remission of all trials (I2 = 0%, P ="/>
 <result pre="the test for the overall effect was significant (P&amp;lt;0.00001). The" exact="total" post="remission rate of proteinuria was obviously higher in the"/>
 <result pre="therapy in all trials and CCTs. OR: odds ratio; CR:" exact="complete" post="remission; PR: partial remission. 3.2 Subgroup analysis of the"/>
 <result pre="trials and CCTs. OR: odds ratio; CR: complete remission; PR:" exact="partial" post="remission. 3.2 Subgroup analysis of the association between efficacy"/>
 <result pre="IFNs and NAs in HBV-GN patients. OR: odds ratio; CR:" exact="complete" post="remission. 3.3 Subgroup analysis of the association between efficacy"/>
 <result pre="of the association between efficacy and age Six studies included" exact="adult" post="patients, and the other two studies included pediatric patients."/>
 <result pre="patients, and the other two studies included pediatric patients. The" exact="adult" post="group had 103 patients, composing 56.6% of the total"/>
 <result pre="The adult group had 103 patients, composing 56.6% of the" exact="total" post="182 patients, and the pediatric group had 79 patients,"/>
 <result pre="pediatric patients (OR = 57.71, 95% CI: 7.21−461.82) and the" exact="adult" post="patients (OR = 6.38, 95% CI: 2.51−16.24) emphasized the"/>
 <result pre="CI: 2.51−16.24) emphasized the good effect of antiviral therapy on" exact="adult" post="patients and pediatric patients (Fig 4). There was no"/>
 <result pre="with pediatric patients (I2 = 0%, P = 0.82) or" exact="adult" post="patients (I2 = 0%, P = 0.43), which shows"/>
 <result pre="age and heterogeneity. Fig 4 CR with antiviral therapy in" exact="adult" post="patients and pediatric patients. OR: odds ratio; CR: complete"/>
 <result pre="in adult patients and pediatric patients. OR: odds ratio; CR:" exact="complete" post="remission. 3.4 Subgroup analysis of groups at the 12-month"/>
 <result pre="CR+PR with at the 12-month follow-up. OR: odds ratio; CR:" exact="complete" post="remission; PR: partial remission. 4. Effects on the eGFR"/>
 <result pre="the 12-month follow-up. OR: odds ratio; CR: complete remission; PR:" exact="partial" post="remission. 4. Effects on the eGFR The renal function"/>
 <result pre="Egger’s test were performed to assess the publication bias for" exact="total" post="remission of proteinuria and suggested the absence of publication"/>
 <result pre="publication bias for total remission of proteinuria and suggested the" exact="absence of" post="publication bias (Begg’s test: P = 0.230; Egger’s test:"/>
 <result pre="were mainly psychiatric problems. The most common events were flu-like" exact="syndrome" post="(50/95, 52.6%), fever (26/95, 27.3%), fatigue (27/95, 28.4%) and"/>
 <result pre="relieved by analgesics. The psychiatric symptoms (21/95, 22.1%), such as" exact="anxiety" post="and loss of interest (n = 6), insomnia (n"/>
 <result pre="such as anxiety and loss of interest (n = 6)," exact="insomnia" post="(n = 8), depression (n = 4) and suicidal"/>
 <result pre="loss of interest (n = 6), insomnia (n = 8)," exact="depression" post="(n = 4) and suicidal ideation (n = 3)."/>
 <result pre="of IFNs. Other symptoms were rare including anorexia, nausea, chills," exact="neutropenia" post="and thrombocytopenia. Compared with IFNs, the side effects in"/>
 <result pre="not reflect the treatment effects, so our study focused on" exact="total" post="remission (CR+PR) and CR. From the numerical results, we"/>
 <result pre="we found that the included patients all experienced benefits in" exact="total" post="remission and CR. However, the CR statistics showed larger"/>
 <result pre="CR. However, the CR statistics showed larger heterogeneity than did" exact="total" post="remission. This finding indicated that the clinical efficacy of"/>
 <result pre="patients was 57.71, which was much larger than that of" exact="adult" post="patients (OR = 6.38). Heterogeneity decreased to I2 ="/>
 <result pre="Heterogeneity decreased to I2 = 0% in both pediatric and" exact="adult" post="patients. The results showed that pediatric patients were more"/>
 <result pre="Panomsak’s study[20] were the main source of influence on CR." exact="Renal" post="pathological examination in these studies revealed that the pathologic"/>
 <result pre="in these studies revealed that the pathologic types were various," exact="IgA nephropathy" post="had a lager proportion. While, almost all of the"/>
 <result pre="these studies revealed that the pathologic types were various, IgA" exact="nephropathy" post="had a lager proportion. While, almost all of the"/>
 <result pre="poor efficacy was age because the standards for eGFR for" exact="adult" post="patients and pediatric patients are not the same, so"/>
 <result pre="the same results[6,7,9,10]. HBeAg seroconversion marks the immune-active phase of" exact="disease" post="transition to the inactive carrier state[26]. Among the included"/>
 <result pre="arbitrary serum HBV DNA level of 105 copies/mL to differentiate" exact="chronic hepatitis" post="B from an inactive carrier state. Another study claimed"/>
 <result pre="serum HBV DNA level of 105 copies/mL to differentiate chronic" exact="hepatitis" post="B from an inactive carrier state. Another study claimed"/>
 <result pre="state. Another study claimed that 33% of patients with HBeAg-negative" exact="chronic hepatitis" post="had HBV DNA levels that were persistently above 105"/>
 <result pre="Another study claimed that 33% of patients with HBeAg-negative chronic" exact="hepatitis" post="had HBV DNA levels that were persistently above 105"/>
 <result pre="these data, we considered that in terms of reflecting the" exact="disease" post="condition, HBeAg clearance could replace serum HBV DNA to"/>
 <result pre="to different pathological types. One is circulating immune complexes of" exact="viral" post="antigen and host antibody, and the other is in"/>
 <result pre="antibody, and the other is in situ immune complexes involving" exact="viral" post="antigens bound to glomerular structures[29]. Previous studies have reported"/>
 <result pre="glomerular structures[29]. Previous studies have reported that HBeAg is the" exact="primary" post="antigen related to subepithelial deposits in patients with HBV-MN[30,31]."/>
 <result pre="HBeAg, were essential in the pathogenesis of HBV-GN. (2) HBV" exact="infection" post="of nephrocytes induces a cytopathic effect[33]. Thus, the hypothesis"/>
 <result pre="apoptosis and proliferation) and HBV replication in renal tissue. Host" exact="immunodeficiency" post="and virus variation are thought to be the most"/>
 <result pre="to persistent HBV infection. (4) HBV in tissue could express" exact="viral" post="proteins or pro-inflammatory cytokines, resulting in renal injury[34]. Human"/>
 <result pre="a small, enveloped, primarily hepatotropic DNA virus[35]. NAs can suppress" exact="viral" post="replication by inhibiting the activity of HBV polymerase in"/>
 <result pre="overestimate, an underestimate, or true estimate of the effect. The" exact="limited" post="number of studies available and patients enrolled in each"/>
 <result pre="all in English and conducted in Asian countries and mostly" exact="limited" post="to China. This geographic concentration is probably the reason"/>
 <result pre="is probably the reason for the high prevalence of HBV" exact="infection" post="in these countries. As a result, our conclusions concerning"/>
 <result pre="safety of antiviral treatments may not apply to European or" exact="American" post="patients. Conclusion In summary, some broad conclusions can be"/>
 <result pre="References 1collab: Collaborators TPO. Global prevalence, treatment, and prevention of" exact="hepatitis" post="B virus infection in 2016: a modelling study. Lancet"/>
 <result pre="Collaborators TPO. Global prevalence, treatment, and prevention of hepatitis B" exact="virus infection" post="in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403."/>
 <result pre="TPO. Global prevalence, treatment, and prevention of hepatitis B virus" exact="infection" post="in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403."/>
 <result pre="2012 Clinical Practice Guideline for the Evaluation and Management of" exact="Chronic" post="Kidney Disease'.Kidney international. 2013;84(3):622–3. 4FabriziF, DixitV, MartinP. Meta-analysis: anti-viral"/>
 <result pre="Clinical Practice Guideline for the Evaluation and Management of Chronic" exact="Kidney" post="Disease'.Kidney international. 2013;84(3):622–3. 4FabriziF, DixitV, MartinP. Meta-analysis: anti-viral therapy"/>
 <result pre="Disease'.Kidney international. 2013;84(3):622–3. 4FabriziF, DixitV, MartinP. Meta-analysis: anti-viral therapy of" exact="hepatitis" post="B virus-associated glomerulonephritis. Alimentary pharmacology &amp;amp; therapeutics. 2006; 24(5):781–788.16918881"/>
 <result pre="virus-associated glomerulonephritis. Alimentary pharmacology &amp;amp; therapeutics. 2006; 24(5):781–788.16918881 5KhedmatH, TaheriS." exact="Hepatitis" post="B virus-associated nephropathy: an International Data Analysis. Iranian Journal"/>
 <result pre="B virus-associated nephropathy: an International Data Analysis. Iranian Journal of" exact="Kidney" post="Diseases. 2010; 4(2):10120404417 6ZhangY, ZhouJH, YinXL, WangFY. Treatment of"/>
 <result pre="Kidney Diseases. 2010; 4(2):10120404417 6ZhangY, ZhouJH, YinXL, WangFY. Treatment of" exact="hepatitis" post="B virus-associated glomerulonephritis: a meta-analysis. World Journal of Gastroenterology."/>
 <result pre="10.3748/wjg.v16.i6.77020135728 7YiZ, JieYW, NanZ. The efficacy of anti-viral therapy on" exact="hepatitis" post="b virus-associated glomerulonephritis: a systematic review and meta-analysis. Annals"/>
 <result pre="RB, TangL, LiP, Zheng XD. Meta-analysis of combined therapy for" exact="adult" post="hepatitis B virus-associated glomerulonephritis. World Journal of Gastroenterology Wjg."/>
 <result pre="TangL, LiP, Zheng XD. Meta-analysis of combined therapy for adult" exact="hepatitis" post="B virus-associated glomerulonephritis. World Journal of Gastroenterology Wjg. 2012;"/>
 <result pre="of the efficacy and safety of nucleotide/nucleoside analog monotherapy for" exact="hepatitis" post="B virus-associated glomerulonephritis. Clinical Nephrology. 2016; 85(1):21–29. 10.5414/CN10864826636326 10YangY,"/>
 <result pre="MaY, ChenDP, ZhuoL, LiWG. A Meta-Analysis of Antiviral Therapy for" exact="Hepatitis" post="B Virus-Associated Membranous Nephropathy. Plos One. 2016; 11(9):e016043710.1371/journal.pone.016043727598699 11Higgins"/>
 <result pre="board of Chinese Journal of Internal Medicine.Summary of symposium on" exact="hepatitis" post="b virus-associated glomerulonephritis. Chin J Intern Med. 1990; 29:518–521."/>
 <result pre="therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for" exact="hepatitis" post="B virus-associated glomerulonephritis with mild to moderate proteinuria:a clinical"/>
 <result pre="and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated" exact="glomerulonephritis" post="with mild to moderate proteinuria:a clinical review of 38"/>
 <result pre="2017; 49(6):1049–1056. 10.1007/s11255-017-1563-528283858 18BhimmaR, CoovadiaHM, KramvisA, AdhikariM, KewMC. Treatment of" exact="hepatitis" post="B virus-associated nephropathy in black children. Pediatric nephrology. 2002;"/>
 <result pre="18BhimmaR, CoovadiaHM, KramvisA, AdhikariM, KewMC. Treatment of hepatitis B virus-associated" exact="nephropathy" post="in black children. Pediatric nephrology. 2002; 17(6):3. 19TangS, LaiMM,"/>
 <result pre="KewMC. Treatment of hepatitis B virus-associated nephropathy in black children." exact="Pediatric" post="nephrology. 2002; 17(6):3. 19TangS, LaiMM, LuiYH, TangCOS, KungNNS, HoYW,"/>
 <result pre="17(6):3. 19TangS, LaiMM, LuiYH, TangCOS, KungNNS, HoYW, et al.Lamivudine in" exact="hepatitis" post="B–associated membranous nephropathy. Kidney International. 2005; 68(4):1750–1758. 10.1111/j.1523-1755.2005.00591.x16164651 20PanomsakS,"/>
 <result pre="LaiMM, LuiYH, TangCOS, KungNNS, HoYW, et al.Lamivudine in hepatitis B–associated" exact="membranous nephropathy." post="Kidney International. 2005; 68(4):1750–1758. 10.1111/j.1523-1755.2005.00591.x16164651 20PanomsakS, LewsuwanS, EiamongS, KanjanabuchT."/>
 <result pre="TangCOS, KungNNS, HoYW, et al.Lamivudine in hepatitis B–associated membranous nephropathy." exact="Kidney" post="International. 2005; 68(4):1750–1758. 10.1111/j.1523-1755.2005.00591.x16164651 20PanomsakS, LewsuwanS, EiamongS, KanjanabuchT. Hepatitis-B"/>
 <result pre="21SunIO, HongYA, ParkHS, ChoiSR, ChoiBS. Experience of Anti-Viral Therapy in" exact="Hepatitis" post="B-Associated Membranous Nephropathy, Including Lamivudine-Resistant Strains. Korean Journal of"/>
 <result pre="27(4):411–416. 10.3904/kjim.2012.27.4.41123269882 22AuJTC, LaiMD, LuiF, AuTC, TamJS, TongKL, et al.Membranous" exact="nephropathy" post="related to hepatitis B virus in adults. N Engl"/>
 <result pre="LaiMD, LuiF, AuTC, TamJS, TongKL, et al.Membranous nephropathy related to" exact="hepatitis" post="B virus in adults. N Engl J Med. 1991;"/>
 <result pre="adults. N Engl J Med. 1991; 324(21):145710.1056/NEJM1991052332421032023605 23LinCY. Treatment of" exact="hepatitis" post="B virus-associated membranous nephropathy with recombinant alpha-interferon.Kidney International. 1995;"/>
 <result pre="J Med. 1991; 324(21):145710.1056/NEJM1991052332421032023605 23LinCY. Treatment of hepatitis B virus-associated" exact="membranous nephropathy" post="with recombinant alpha-interferon.Kidney International. 1995; 47(1):225–230. 10.1038/ki.1995.277731150 24IzzedineH, Launay-VacherV,"/>
 <result pre="Med. 1991; 324(21):145710.1056/NEJM1991052332421032023605 23LinCY. Treatment of hepatitis B virus-associated membranous" exact="nephropathy" post="with recombinant alpha-interferon.Kidney International. 1995; 47(1):225–230. 10.1038/ki.1995.277731150 24IzzedineH, Launay-VacherV,"/>
 <result pre="International. 1995; 47(1):225–230. 10.1038/ki.1995.277731150 24IzzedineH, Launay-VacherV, DerayG. Antiviral Drug-Induced Nephrotoxicity." exact="American" post="Journal of Kidney Diseases. 2005; 45(5):804–817. 10.1053/j.ajkd.2005.02.01015861345 25KaraAV, YıldırımY,"/>
 <result pre="10.1038/ki.1995.277731150 24IzzedineH, Launay-VacherV, DerayG. Antiviral Drug-Induced Nephrotoxicity. American Journal of" exact="Kidney" post="Diseases. 2005; 45(5):804–817. 10.1053/j.ajkd.2005.02.01015861345 25KaraAV, YıldırımY, OzcicekF, AldemirMN, ArslanY,"/>
 <result pre="of entecavir, tenofovir and telbivudine treatment on renal functions in" exact="chronic hepatitis" post="B patients. Acta Gastroenterol Belg. 2019; 82(2):273–277. 31314188 26LiawYF."/>
 <result pre="entecavir, tenofovir and telbivudine treatment on renal functions in chronic" exact="hepatitis" post="B patients. Acta Gastroenterol Belg. 2019; 82(2):273–277. 31314188 26LiawYF."/>
 <result pre="seroconversion as an important end point in the treatment of" exact="chronic hepatitis" post="B. Hepatol Int. 2009; 3(3):425–33. 10.1007/s12072-009-9140-319669245 27LokAS, HeathcoteEJ, HoofnagleJH."/>
 <result pre="as an important end point in the treatment of chronic" exact="hepatitis" post="B. Hepatol Int. 2009; 3(3):425–33. 10.1007/s12072-009-9140-319669245 27LokAS, HeathcoteEJ, HoofnagleJH."/>
 <result pre="Hepatol Int. 2009; 3(3):425–33. 10.1007/s12072-009-9140-319669245 27LokAS, HeathcoteEJ, HoofnagleJH. Management of" exact="Hepatitis" post="B 2000, Summary ofa Workshop. Gastroenterology. 2001; 120:1828–1853. 10.1053/gast.2001.2483911375963"/>
 <result pre="LokASF. Quantitative serum HBV DNA levels during different stages of" exact="chronic hepatitis" post="B infection. Hepatology. 2002; 36(6):1408–1415. 10.1053/jhep.2002.3694912447866 29LaiAS, LaiKN. Viral"/>
 <result pre="Quantitative serum HBV DNA levels during different stages of chronic" exact="hepatitis" post="B infection. Hepatology. 2002; 36(6):1408–1415. 10.1053/jhep.2002.3694912447866 29LaiAS, LaiKN. Viral"/>
 <result pre="chronic hepatitis B infection. Hepatology. 2002; 36(6):1408–1415. 10.1053/jhep.2002.3694912447866 29LaiAS, LaiKN." exact="Viral" post="nephropathy. Nature Clinical Practice Nephrology. 2006; 2(5):254–262. 10.1038/ncpneph016616932438 30LinCY."/>
 <result pre="Viral nephropathy. Nature Clinical Practice Nephrology. 2006; 2(5):254–262. 10.1038/ncpneph016616932438 30LinCY." exact="Hepatitis" post="B Virus-Associated Membraneous Nephropathy: Clinical Features, Immunological Profiles and"/>
 <result pre="2(5):254–262. 10.1038/ncpneph016616932438 30LinCY. Hepatitis B Virus-Associated Membraneous Nephropathy: Clinical Features," exact="Immunological" post="Profiles and Outcome. Nephron. 1990; 55(1):37–44. 10.1159/0001859162191232 31ItoH, HattoriS,"/>
 <result pre="10.1159/0001859162191232 31ItoH, HattoriS, MatsudaI, AmamiyaS, HajikanoH, YoshizawaH, et al.Deposition of" exact="hepatitis" post="B e antigen in membranous glomerulonephritis: Identification by F(ab))fragments"/>
 <result pre="1984; 26:338–341. 10.1038/ki.1984.1786513277 32TakekoshiY, TochimaruH, NagataY, ItamiN. Immunopathogenetic mechanisms of" exact="hepatitis" post="B virus-related glomerulopathy.Kidney International Supplement. 1991; 35(35):S34.1837572 33BhimmaR, CoovadiaHM."/>
 <result pre="hepatitis B virus-related glomerulopathy.Kidney International Supplement. 1991; 35(35):S34.1837572 33BhimmaR, CoovadiaHM." exact="Hepatitis" post="B Virus-Associated Nephropathy. American Journal of Nephrology. 2004; 24(2):198–211."/>
 <result pre="International Supplement. 1991; 35(35):S34.1837572 33BhimmaR, CoovadiaHM. Hepatitis B Virus-Associated Nephropathy." exact="American" post="Journal of Nephrology. 2004; 24(2):198–211. 10.1159/00007706514988643 34SegererS, NelsonPJ, NdorffD."/>
 <result pre="basic science to pathophysiologic and therapeutic studies. Journal of the" exact="American" post="Society of Nephrology Jasn. 2000; 11(1):15210616852 35SeegerC, MasonWS. Hepatitis"/>
 <result pre="the American Society of Nephrology Jasn. 2000; 11(1):15210616852 35SeegerC, MasonWS." exact="Hepatitis" post="B virus biology.Microbiology&amp;amp;Molecular Biology Reviews. 2000; 64(1):51.10704474 36GhanyM, LiangTJ."/>
 <result pre="64(1):51.10704474 36GhanyM, LiangTJ. Drug Targets and Molecular Mechanisms of Drug" exact="Resistance" post="in Chronic Hepatitis B. Gastroenterology. 2007; 132(4):1574–1585. 10.1053/j.gastro.2007.02.03917408658 37PeiRJ,"/>
 <result pre="LiangTJ. Drug Targets and Molecular Mechanisms of Drug Resistance in" exact="Chronic" post="Hepatitis B. Gastroenterology. 2007; 132(4):1574–1585. 10.1053/j.gastro.2007.02.03917408658 37PeiRJ, ChenXW, LuM."/>
 <result pre="Drug Targets and Molecular Mechanisms of Drug Resistance in Chronic" exact="Hepatitis" post="B. Gastroenterology. 2007; 132(4):1574–1585. 10.1053/j.gastro.2007.02.03917408658 37PeiRJ, ChenXW, LuM. Control"/>
 <result pre="B. Gastroenterology. 2007; 132(4):1574–1585. 10.1053/j.gastro.2007.02.03917408658 37PeiRJ, ChenXW, LuM. Control of" exact="hepatitis" post="B virus replication by interferons and toll-like receptor signaling"/>
</results>
